Gar transformylase inhibitor
CA 2002765 A1 · Owner: Pennsylvania State University (The) · Inventors: Inglese, James; Benkovic, Stephen J.; Blatchly, Richard A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Docket No. 38,243, GAR TRANSFORMYLASE INHIBITOR ABSTRACT OF THE DISCLOSURE, The present invention is directed to several multisubstrate adduct inhibitors of glycinamide ribonucleotidew transformylase (GAR TFase; E.C. 2.1.2.2) a folate-requiring enzyme of de novo purine biosynthesis. The compounds of the present invention will be useful to provide anti-gout and/or anti-neoplastic therapeutic agents or will serve as potentiators for other such agents. The most preferred, potent tight-binding multisubstrate adduct inhibitor of glycinamide ribonucleotide transformylase is N10-5'-phosphoribosyl-1'-.beta.-aminocarbonylmethyl- 1-thioacatyl-5,8-dideazafolate, which has the chemical formula:, …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 10, 1989. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended November 10, 2009.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 10, 2011.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.